Neuralink PRIME Study

Neuralink PRIME Study

The PRIME study is Neuralink's first-in-human early-feasibility study of the N1 Implant and R1 surgical robot for control of external devices.

What the study is asking

The ClinicalTrials.gov record says the study is designed to evaluate initial clinical safety and device functionality in participants with tetraparesis or tetraplegia. Its outcomes include device-related adverse events and measures of brain-computer-interface performance and use.

That question is narrower than many public discussions of Neuralink. PRIME does not establish that the device restores walking, treats every form of paralysis, or is ready for routine clinical use.

Evidence state

The registry listed the study as recruiting, estimated enrollment of 15, an estimated primary completion in June 2026, an estimated study completion in January 2031, and no posted results when checked on July 28, 2026. An estimated date does not establish that analysis or reporting is complete. Neuralink has published sponsor updates about individual participants, including computer use, games, design software, hours of use, and technical changes.

Those updates can show what the company and participants reported. They cannot replace the study's completed analysis, adverse-event reporting, long-term follow-up, or independent review.

Regulatory meaning

The study is conducted under an investigational device exemption. That regulatory pathway allows a device to be used in a clinical investigation when the applicable requirements are met. It does not grant marketing approval.

Venture Step conversation

E010 was recorded soon after the first public participant demonstration. The canonical article preserves the importance of that experience while correcting the original description of the study as an approved treatment.

Editorial and verification notes

Study status, enrollment, locations, eligibility, outcomes, and results can change. Recheck the ClinicalTrials.gov record and applicable regulator before publication. This note does not advise anyone to join, leave, or make a medical decision about a clinical study.